PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Metastatic Hormone Refractory Prostate Cancer Clinical Trial

Official title:
A Phase II Study of PHA-739358 in Patients With Metastatic Hormone Refractory Prostate Cancer

Status Completed

Clinical Trial Summary

To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule for further investigation.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Metastatic Hormone Refractory Prostate Cancer
Prostatic Neoplasms

Clinical Trial Details

NCT number	NCT00766324
Study type	Interventional
Source	Nerviano Medical Sciences
Contact
Status	Completed
Phase	Phase 2
Start date	September 2007
Completion date	April 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00411528` - Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer	Phase 2
Completed	`NCT00636090` - Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001	N/A
Active, not recruiting	`NCT04477512` - Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)	Phase 1